Compared to CTLA-4 inhibitors, PD-1/PD-L1 inhibitors are more widely used in HCC, and although they are generally well-tolerated, they may still cause immune-related adverse events (irAEs), such as fatigue, rash, gastrointestinal reactions, and autoimmune thyroid diseases. Here, PDCD1 is linked to hepatocellular carcinoma.